Home › Compare › DLAD vs MRK

DLAD vs MRK: Dividend Comparison 2026

DLAD yields 5000000.00% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DLAD wins by $4.651129742658086e+43M in total portfolio value
10 years
DLAD
DLAD
● Live price
5000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.651129742658086e+43M
Annual income
$46,509,467,603,334,410,000,000,000,000,000,000,000,000,000,000,000.00
Full DLAD calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — DLAD vs MRK

📍 DLAD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDLADMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DLAD + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
DLAD pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DLAD
Annual income on $10K today (after 15% tax)
$425,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$39,533,047,462,834,250,000,000,000,000,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, DLAD beats the other by $39,533,047,462,834,250,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DLAD + MRK for your $10,000?

DLAD: 50%MRK: 50%
100% MRK50/50100% DLAD
Portfolio after 10yr
$2.325564871329043e+43M
Annual income
$23,254,733,801,667,206,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

DLAD
No analyst data
Altman Z
-1183.7
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DLAD buys
0
MRK buys
0
No recent congressional trades found for DLAD or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDLADMRK
Forward yield5000000.00% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$4.651129742658086e+43M$30.7K ✓
Annual income after 10y$46,509,467,603,334,410,000,000,000,000,000,000,000,000,000,000,000.00 ✓$950.29
Total dividends collected$4.651117771440442e+43M$6.1K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DLAD vs MRK ($10,000, DRIP)

YearDLAD PortfolioDLAD Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$500,010,700$500,000,000.00$11,192$351.54+$500.00M → DLAD
2$23,365,520,992,757$23,364,985,981,308.41$12,524$392.70+$23365520.98M → DLAD
3$1,020,442,548,175,215,100$1,020,417,547,067,752,800.00$14,015$438.65+$1020442548175.20M → DLAD
4$41,650,346,151,752,480,000,000$41,649,254,278,225,940,000,000.00$15,682$489.96+$41650346151752480.00M → DLAD
5$1,588,787,048,835,084,000,000,000,000$1,588,742,482,964,701,800,000,000,000.00$17,547$547.23+$1.588787048835084e+21M → DLAD
6$56,640,860,400,245,200,000,000,000,000,000$56,639,160,398,102,940,000,000,000,000,000.00$19,632$611.16+$5.66408604002452e+25M → DLAD
7$1,887,170,449,619,629,000,000,000,000,000,000,000$1,887,109,843,899,000,500,000,000,000,000,000,000.00$21,963$682.53+$1.887170449619629e+30M → DLAD
8$58,763,764,792,023,670,000,000,000,000,000,000,000,000$58,761,745,519,642,570,000,000,000,000,000,000,000,000.00$24,571$762.18+$5.876376479202367e+34M → DLAD
9$1,710,115,183,602,138,000,000,000,000,000,000,000,000,000,000$1,710,052,306,373,811,000,000,000,000,000,000,000,000,000,000.00$27,486$851.08+$1.710115183602138e+39M → DLAD
10$46,511,297,426,580,864,000,000,000,000,000,000,000,000,000,000,000$46,509,467,603,334,410,000,000,000,000,000,000,000,000,000,000,000.00$30,745$950.29+$4.651129742658086e+43M → DLAD

DLAD vs MRK: Complete Analysis 2026

DLAD — Stock

DealerAdvance Inc. esigns, develops, markets, sells, and installs web-based application software and database systems for auto dealer–customer relationship management

Full DLAD Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this DLAD vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DLAD vs SCHDDLAD vs JEPIDLAD vs ODLAD vs KODLAD vs MAINDLAD vs JNJDLAD vs ABBVDLAD vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.